Table S1. Cavity prevalence in MDR-TB and DS-TB patients.
| Study | Cavity prevalence | |
|---|---|---|
| MDR-TB | DS-TB | |
| Chuchottaworn et al. (20) (by CXR) | 63.4% | 23.4% |
| Joshi et al. (21) | 53% | – |
| Chung et al. (22) | 77% | 38% |
| Kim HC et al. (23) | 62% | 34% |
| Zahirifard et al. (24) | ||
| By CXR | 80% | – |
| By CT | 100% | – |
| Kim SH et al. (25) | 85% | 55% |
| Yeom et al. (26) | 90% | 64% |
| Kim W et al. (27) | 68.2% | – |
| Cha et al. (28) | 69% | 36% |
| Kahkouee et al. (29) | 76.7% | – |
| Cheon et al. (32) | 79.1% | – |
| Lee et al. (33) | 76.5% | – |
| Li et al. (29) | ||
| Cavity in consolidation | 48.3% | 47.2% |
| Cavitary nodule or mass | 57.3% | 38.2% |
| Song et al. (31) | 15.4% | 32.6% |
| 1–2 cavity | ||
| ≥3 cavity | 33.3% | 37.0% |